As treatment guidelines are constantly being updated to account for new treatment options for psoriatic arthritis (PsA), researchers of a new study in Joint Bone Spine have outlined recommendations by ...

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Long-term PsA treatment may be on its way Improvements were noted in patients' physical function, enthesitis, dactylitis, and skin manifestations in a five-year trial. Golimumab, a tumor necrosis ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and weight reduction endpoints, according to topline results announced by Eli ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

The updated guidelines encompass 7 overarching principles and 11 recommendations concerning treatment approaches and pharmacological therapies for psoriatic arthritis. The European Alliance of ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Findings showed 31.7% of patients receiving ixekizumab and tirzepatide achieved both ACR50 and at least 10% weight loss vs 0.8% on ixekizumab monotherapy. Topline data were announced from a phase 3b ...